22 Sep 2017 | 2:57 AM
Research Report
Weekly

Equity Research Report: Master Pick-Ranbaxy Lab

Ranbaxy has received the regulatory approval to launch India’s first NCE (New Chemical Entity), Synriam™ in seven African countries. The product has been launched in Uganda and will be made available in other countries towards end of January 2015.
09 Jan 2015 | 05:45 PM

Amid excessive volatility across the board, Ranbaxy is trading stable and formed a fresh buying pivot on the weekly chart. Traders are advised to accumulate the stock between 620-CMP (631.05) with closing below stop loss of 595 for the target of  710.